RU2145958C1 - 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция - Google Patents

3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция Download PDF

Info

Publication number
RU2145958C1
RU2145958C1 RU94042903A RU94042903A RU2145958C1 RU 2145958 C1 RU2145958 C1 RU 2145958C1 RU 94042903 A RU94042903 A RU 94042903A RU 94042903 A RU94042903 A RU 94042903A RU 2145958 C1 RU2145958 C1 RU 2145958C1
Authority
RU
Russia
Prior art keywords
compound
crystalline
alkyl
hydroxyphenyl
dimethyl
Prior art date
Application number
RU94042903A
Other languages
English (en)
Russian (ru)
Other versions
RU94042903A (ru
Inventor
Алан Фрэнк Скотт
Эдвард Претер Дуглас
Алан Уорд Джеффри
Арнольд Вернер Джон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of RU94042903A publication Critical patent/RU94042903A/ru
Application granted granted Critical
Publication of RU2145958C1 publication Critical patent/RU2145958C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU94042903A 1993-12-08 1994-12-02 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция RU2145958C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/164,074 1993-12-08
US08/164.074 1993-12-08
US08/164,074 US5434171A (en) 1993-12-08 1993-12-08 Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates

Publications (2)

Publication Number Publication Date
RU94042903A RU94042903A (ru) 1996-10-27
RU2145958C1 true RU2145958C1 (ru) 2000-02-27

Family

ID=22592858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042903A RU2145958C1 (ru) 1993-12-08 1994-12-02 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция

Country Status (30)

Country Link
US (1) US5434171A (enExample)
EP (3) EP0984004A3 (enExample)
JP (2) JP3834075B2 (enExample)
KR (1) KR100356239B1 (enExample)
CN (2) CN1057294C (enExample)
AT (1) ATE200279T1 (enExample)
AU (1) AU681198B2 (enExample)
BR (1) BR9404842A (enExample)
CA (1) CA2137221C (enExample)
CO (1) CO4290427A1 (enExample)
CZ (1) CZ290559B6 (enExample)
DE (1) DE69427017T2 (enExample)
DK (1) DK0657428T3 (enExample)
ES (1) ES2155844T3 (enExample)
FI (2) FI106455B (enExample)
GR (1) GR3036136T3 (enExample)
HU (1) HUT71489A (enExample)
IL (1) IL111843A (enExample)
MY (1) MY121543A (enExample)
NO (1) NO302884B1 (enExample)
NZ (1) NZ270039A (enExample)
PE (1) PE41495A1 (enExample)
PL (1) PL181734B1 (enExample)
PT (1) PT657428E (enExample)
RU (1) RU2145958C1 (enExample)
SI (1) SI0657428T1 (enExample)
TW (1) TW290540B (enExample)
UA (1) UA52577C2 (enExample)
YU (2) YU49312B (enExample)
ZA (1) ZA949584B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2373936C2 (ru) * 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
HN1999000149A (es) 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912417D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912416D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP1404323B1 (en) * 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
US20030068829A1 (en) * 2001-06-25 2003-04-10 Symyx Technologies, Inc. High throughput crystallographic screening of materials
PT2939696E (pt) 2001-10-18 2016-06-17 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
US6794510B2 (en) * 2002-08-08 2004-09-21 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
BRPI0409133B8 (pt) 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US20050148630A1 (en) * 2003-12-02 2005-07-07 Carpenter Randall L. Methods of preventing and treating non-opioid induced gastrointestinal dysfunction
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
RS53279B (sr) * 2003-12-16 2014-08-29 Nektar Therapeutics Monodisperzne smeše pegilisanog naloksola
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
US20050240177A1 (en) * 2004-04-26 2005-10-27 Packaging Service Corporation Of Kentucky Electrosurgical forceps
US7700626B2 (en) * 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
US20060211733A1 (en) * 2005-03-04 2006-09-21 Adolor Corporation Methods of preventing and treating opioid bowel dysfunction
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
BRPI0608818A2 (pt) * 2005-03-07 2010-01-26 Univ Chicago uso de antagonista opióides para atenuação de proliferação e migração de células endoteliais
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
CN101262867A (zh) * 2005-07-01 2008-09-10 叶林发现公司 用于治疗肥胖的mao-b抑制剂
US7914776B2 (en) * 2005-10-07 2011-03-29 Adolor Corporation Solid dispersions of opioid antagonists
US20070092576A1 (en) * 2005-10-20 2007-04-26 Adolor Corporation Compositions containing opioid antagonists
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
CN100383121C (zh) * 2006-03-07 2008-04-23 天津泰普药品科技发展有限公司 阿韦苄酯化合物及其制备方法和以该化合物制备阿韦莫哌的工艺
JP5176188B2 (ja) 2006-04-21 2013-04-03 ディーエスエム アイピー アセッツ ビー．ブイ． オピオイド受容体拮抗薬の使用
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2670136A1 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
CA2682125C (en) 2007-03-29 2015-06-16 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
EP2134718A2 (en) 2007-03-29 2009-12-23 Progenics Pharmaceuticals, Inc. Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof
CA2713568C (en) 2008-02-06 2016-09-20 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2331140B1 (en) 2008-08-11 2018-07-04 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
CN101429154B (zh) * 2008-11-14 2011-01-05 天津泰普药品科技发展有限公司 无水阿维莫泮及其药物组合物
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
SMT201900357T1 (it) 2009-12-04 2019-07-11 Alkermes Pharma Ireland Ltd Derivati di morfinano per trattamento di abuso di sostanze stupefacenti
WO2011161646A2 (en) 2010-06-25 2011-12-29 Ranbaxy Laboratories Limited Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
CN103360302B (zh) * 2012-03-29 2015-08-26 北大方正集团有限公司 阿维莫泮的纯化方法
US10314839B2 (en) 2014-10-20 2019-06-11 Elysium Therapeutics, Inc. Diversion-resistant opioid formulations
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
EP0506468A1 (en) * 1991-03-29 1992-09-30 Eli Lilly And Company N-substituted 4-phenyl-piperidine opioid-antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136040A (en) * 1991-02-26 1992-08-04 Eli Lilly And Company Preparation of substituted tetrahydropyridines
CZ284993B6 (cs) * 1991-03-29 1999-04-14 Eli Lilly And Company Derivát piperidinu

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891379A (en) * 1987-04-16 1990-01-02 Kabushiki Kaisha Kobe Seikosho Piperidine opioid antagonists
EP0506468A1 (en) * 1991-03-29 1992-09-30 Eli Lilly And Company N-substituted 4-phenyl-piperidine opioid-antagonists
US5250542A (en) * 1991-03-29 1993-10-05 Eli Lilly And Company Peripherally selective piperidine carboxylate opioid antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Машковский М.Д. Лекарственные средства. - М.: Медицина, 1984, ч.2, с.10, 20, 21. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2373936C2 (ru) * 2003-04-08 2009-11-27 Проджиникс Фармасьютикалз, Инк. Применение метилналтрексона для лечения синдрома раздраженного кишечника

Also Published As

Publication number Publication date
NZ270039A (en) 1996-08-27
YU82304A (sh) 2006-03-03
CA2137221A1 (en) 1995-06-09
YU70294A (sh) 1997-07-31
MY121543A (en) 2006-02-28
TW290540B (enExample) 1996-11-11
KR100356239B1 (ko) 2002-12-26
CZ299294A3 (en) 1995-10-18
CN1121387C (zh) 2003-09-17
AU681198B2 (en) 1997-08-21
ES2155844T3 (es) 2001-06-01
YU49312B (sh) 2005-06-10
BR9404842A (pt) 1995-08-08
JPH07215937A (ja) 1995-08-15
UA52577C2 (uk) 2003-01-15
CN1223257A (zh) 1999-07-21
CN1057294C (zh) 2000-10-11
PT657428E (pt) 2001-07-31
NO944644D0 (no) 1994-12-02
HK1013826A1 (en) 1999-09-10
FI106455B (fi) 2001-02-15
ATE200279T1 (de) 2001-04-15
DK0657428T3 (da) 2001-05-07
PL306068A1 (en) 1995-06-12
NO302884B1 (no) 1998-05-04
ZA949584B (en) 1996-06-03
EP0657428A1 (en) 1995-06-14
CO4290427A1 (es) 1996-04-17
EP0984004A2 (en) 2000-03-08
DE69427017D1 (de) 2001-05-10
GR3036136T3 (en) 2001-09-28
FI20000353L (fi) 2000-02-17
IL111843A0 (en) 1995-03-15
FI945703A0 (fi) 1994-12-02
RU94042903A (ru) 1996-10-27
JP2006070042A (ja) 2006-03-16
IL111843A (en) 2000-02-29
EP0984004A3 (en) 2003-10-15
NO944644L (no) 1995-06-09
CZ290559B6 (cs) 2002-08-14
EP1607387A3 (en) 2007-01-03
DE69427017T2 (de) 2001-09-06
KR950017957A (ko) 1995-07-22
HUT71489A (en) 1995-11-28
JP3834075B2 (ja) 2006-10-18
CN1111239A (zh) 1995-11-08
EP1607387A2 (en) 2005-12-21
PE41495A1 (es) 1995-11-28
SI0657428T1 (en) 2001-08-31
FI106860B (fi) 2001-04-30
HU9403466D0 (en) 1995-02-28
EP0657428B1 (en) 2001-04-04
AU7917094A (en) 1995-06-15
CA2137221C (en) 2011-02-22
US5434171A (en) 1995-07-18
FI945703L (fi) 1995-06-09
PL181734B1 (pl) 2001-09-28

Similar Documents

Publication Publication Date Title
RU2145958C1 (ru) 3,4,4-трехзамещенные пиперидинил-n-алкилкарбоксилаты и промежуточные соединения, способ их получения и фармацевтическая композиция
US5270328A (en) Peripherally selective piperidine opioid antagonists
KR100229117B1 (ko) 피페리딘 유도체
JPH10101565A (ja) 胃腸血行障害を治療および予防するための医薬製剤を製造するためのベンズアゼピン−ｎ−酢酸誘導体の使用
JPS6049192B2 (ja) 新規置換ベンズアミド、その製造方法及びこれを有効成分とする向精神薬
DE69215965T2 (de) Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung
RS61515B1 (sr) Soli ili kokristali 3-(3-dimetilamino-1-etil-2-metil-propil)-fenola
JPH08176145A (ja) アロイル−ピペリジン誘導体
PT85628B (pt) Processo para a preparacao de derivados de piperidina
JP2001500850A (ja) 非―ペプチドボンベシン受容体アンタゴニスト
AU714523B2 (en) Chromone derivatives
JPH021439A (ja) ジアミン化合物、その製法及び該化合物を含有する高血圧症及び炎症を治療するための医薬
US9463187B2 (en) Methylphenidate derivatives and uses of them
JP2002507600A (ja) ピペリジジニルおよびｎ−アミジノピペリジニル誘導体
JP2650739B2 (ja) 分割化アミノピロリジン神経防護剤
JP2730135B2 (ja) 酸アミド誘導体
HK1027558A (en) Trisubstituted-piperidinyl-n-alkylcarboxylates as opioid antagonists
HK1013826B (en) Preparation of 3,4,4-trisubstitutedpiperidinyl-n-alkylcarboxylates and intermediates, useful as opioid antagonists
HK1084950A (en) 3,4,4-trisubstituted piperidine derivatives and their use as opioid antagonists
JP2009500350A (ja) 肥満症及び関連障害の治療用の新規アミノ酸誘導体
JPH0788334B2 (ja) Ｎ−メチルフエニルセリン誘導体
EP0998458A1 (fr) Nouveaux derives benzamides stimulants de la motricite gastrointestinale haute et basse

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20101203